Patents by Inventor Glenn Noronha

Glenn Noronha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050282814
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: April 13, 2005
    Publication date: December 22, 2005
    Applicant: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20050245524
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: April 7, 2005
    Publication date: November 3, 2005
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Xianchang Gong, John Hood, Chi Mak, Andrew McPherson, Ved Pathak, Joel Renick, Richard Soll, Ute Splittgerber, Wolfgang Wrasdilo, Ningning Zhao, Elena Dneprovskaia
  • Publication number: 20050191761
    Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. These biosensor molecules address the problem of obtaining fluorescence emission at wavelengths greater than about 500 nm. Biosensor molecules generally include an (1) an acridine-based fluorophore, (2) a linker moiety and (3) a boronate substrate recognition/binding moiety, which binds polyhydroxylate analytes, such as glucose. These biosensor molecules further include a “switch” element that is drawn from the electronic interactions among these submolecular components. This fluorescent switch is generally “off” in the absence of bound polyhydroxylate analyte and is generally “on” in the presence of bound polyhydroxylate analyte. Thus, the reversible binding of a polyhydroxylate analyte essentially turns the fluorescent switch “on” and “off”.
    Type: Application
    Filed: September 12, 2001
    Publication date: September 1, 2005
    Inventors: Aaron Heiss, Joseph Walsh, David Vachon, Glenn Noronha, Jonathan Reilly, Bill Ponder, William Van Antwerp
  • Patent number: 6927246
    Abstract: Improved polymer matrices which incorporate fluorescent biosensor molecules as well as methods of making and using these polymer matrices are described. Such matrices can be used in fluorescent biosensors and biosensor systems, including those which are used in the detection of polyhydroxylated analytes such as glucose. The properties of the polymer matrices of the invention renders biosensors utilizing such matrices particularly well-suited for detecting and measuring in-vivo glucose concentrations.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: August 9, 2005
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Glenn Noronha, Jonathan Reilly, Joseph C. Walsh, Brooks Cochran, Aaron M. Heiss, Bill C. Ponder, David J. Vachon
  • Publication number: 20040167198
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: October 2, 2003
    Publication date: August 26, 2004
    Applicant: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Patent number: 6766183
    Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. Embodiments of these biosensor molecules exhibit fluorescence emission at wavelengths greater than about 650 nm. Typical biosensor molecules include a fluorophore that includes an iminium ion, a linker moiety that includes a group that is an anilinic type of relationship to the fluorophore and a boronate substrate recognition/binding moiety, which binds glucose. The fluorescence molecules modulated by the presence or absence of polyhydroxylated analytes such as glucose. This property of these molecules of the invention, as well as their ability to emit fluorescent light at greater than about 650 nm, renders these biosensor molecules particularly well-suited for detecting and measuring in-vivo glucose concentrations.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: July 20, 2004
    Assignees: Medtronic MiniMed, Inc., The Regents of the University of California
    Inventors: Joseph C. Walsh, Aaron M. Heiss, Glenn Noronha, David J. Vachon, Stephen M. Lane, Joe H. Satcher, Jr., Thomas A. Peyser, William Peter Van Antwerp, John Joseph Mastrototaro
  • Publication number: 20040074785
    Abstract: Embodiments of the invention provide analyte sensors having stabilized coating compositions and methods for making such sensors. Illustrative embodiments include electrochemical glucose sensors having stabilized glucose oxidase coatings that are generated for example, via spin coating processes.
    Type: Application
    Filed: October 18, 2002
    Publication date: April 22, 2004
    Inventors: James D. Holker, John J. Mastrototaro, Glenn Noronha, Rajiv Shah, Yanan Zhang, Udo Hoss, Kevin D. Branch
  • Publication number: 20020197724
    Abstract: Improved polymer matrices which incorporate fluorescent biosensor molecules as well as methods of making and using these polymer matrices are described. Such matrices can be used in fluorescent biosensors and biosensor systems, including those which are used in the detection of polyhydroxylated analytes such as glucose. The properties of the polymer matrices of the invention renders biosensors utilizing such matrices particularly well-suited for detecting and measuring in-vivo glucose concentrations.
    Type: Application
    Filed: February 14, 2002
    Publication date: December 26, 2002
    Inventors: Glenn Noronha, Jonathan Reilly, Joseph C. Walsh, Brooks Cochran, Aaron M. Heiss, Bill C. Ponder, David J. Vachon
  • Publication number: 20020193672
    Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. Embodiments of these biosensor molecules exhibit fluorescence emission at wavelengths greater than about 650 nm. Typical biosensor molecules include a fluorophore that includes an iminium ion, a linker moiety that includes a group that is an anilinic type of relationship to the fluorophore and a boronate substrate recognition/binding moiety, which binds glucose. The fluorescence molecules modulated by the presence or absence of polyhydroxylated analytes such as glucose. This property of these molecules of the invention, as well as their ability to emit fluorescent light at greater than about 650 nm, renders these biosensor molecules particularly well-suited for detecting and measuring in-vivo glucose concentrations.
    Type: Application
    Filed: December 28, 2001
    Publication date: December 19, 2002
    Inventors: Joseph C. Walsh, Aaron M. Heiss, Glenn Noronha, David J. Vachon, Stephen M. Lane, Joe H. Satcher, Thomas A. Peyser, William Peter Van Antwerp, John Joseph Mastrototaro